Former Sanofi Executive Named CEO of Synta PharmaceuticalsBy
Synta Pharmaceuticals Corp. has named
Synta Pharmaceuticals Corp, based in Lexington, Massachusetts,. is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule drugs to treat severe medical conditions, including cancer and chronic inflammatory diseases. Its lead compound is ganetespib, in Phase II/III development to treat various cancers. In preclinical models, ganetespib was shown to inhibit a molecular chaperone called Hsp90, essential to the function of many of the most fundamental drivers of cancer cell growth and proliferation. Treatment with ganetespib has been shown in preclinical models to reduce some aggressive features of tumors, such as the ability to induce the growth of new blood vessels (angiogenesis), to spread to other organs in the body (metastasis), and to resist attack by traditional therapies (chemo-resistance).
She began her career at
Source: Synta Pharmaceuticals